Helix BioPharma Secures $3 Million Through Private Placement

Helix BioPharma ( (TSE:HBP) ) has provided an update.

Helix BioPharma Corp. has successfully closed a private placement of 4,000,000 common shares, raising CAD$3,000,000. The proceeds will be used for working capital, subject to final approval by the Toronto Stock Exchange, with a hold period of four months and one day. This financial move is expected to support the company’s ongoing operations and its strategic positioning in the immune-oncology sector.

More about Helix BioPharma

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company focused on developing unique immune-oncology therapies for cancer prevention and treatment, leveraging its proprietary DOS47 technological platform. The company is publicly traded on the TSX, OTC PINK, and Frankfurt exchanges.

YTD Price Performance: -1.74%

Average Trading Volume: 13,142

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: C$41.42M

For an in-depth examination of HBP stock, go to TipRanks’ Stock Analysis page.